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Background
IL-13Ra2 is recognized as one of the candidate genes
significantly associated with pancreatic cancer risk. Pre-
viously, we have demonstrated that IL-13Ra2 is over-
expressed in ~70% of human pancreatic cancer samples.
We have also shown that IL-13 can mediate invasion
and metastasis of human pancreatic cancer cells through
IL-13Ra2 both in vitro and in an in vivo tumor models.
Based on these results, we hypothesized that IL-13Ra2
expression in pancreatic cancer may be related to overall
survival of subjects following surgical resection.
Methods
Between 1996 and 2012 we obtained 107 samples from
NTT Medical Center Tokyo and 129 samples from
Yokohama City University Hospital, Japan. Immunohis-
tochemical staining (IHC) for IL-13Ra2 was performed
and the results analyzed independently by each hospi-
tal’s pathologists. The level of IL-13Ra2 staining inten-
sity (0 to 3+) was used to categorize the specimens as
strong (2+ and 3+) or weak expressers (0 and 1+).
Results
By Kaplan-Meier method, subjects expressing strong IL-
13Ra2 on their tumors survived significantly shorter dura-
tion compared to those with weak expression (p = 0.024).
Further analysis demonstrated that the level of IL-13Ra2
expression was inversely correlated with survival time and
invasion, but not with tumor staging and histological
grade. We are currently examining the correlation
between a variety of other clinical factors and IL-13Ra2
expression using Spearman’s rank correlation test.
Conclusions
In summary, our preliminary results suggest that
IL-13Ra2 expression has an important role in prognosis
and may be critical in overall survival of pancreatic cancer
patients.
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